Genetic Signatures has appointed experienced life sciences executive Maria Halasz as its new Chief Executive Officer, marking a leadership transition as the molecular diagnostics company moves into its next phase of international growth.
Based in Sydney, Ms Halasz brings more than two decades of senior executive, board, and capital markets experience, with a strong track record in commercialisation, corporate strategy, and investor engagement across the life sciences and healthcare sectors. Her appointment follows an extensive career working with publicly listed companies operating in highly regulated global markets.
Ms Halasz is best known for her 14-year tenure as Chief Executive Officer and Managing Director of Anagenics, where she led the company through multiple capital raisings, asset acquisitions, restructures, and licensing transactions. During that period, she worked closely with both institutional and retail investors, building deep expertise in public-market engagement and long-term value creation.
Genetic Signatures Chair Caroline Waldron said the Board viewed the appointment as a strategic fit for the company’s growth ambitions. She highlighted Ms Halasz’s rare combination of leadership capability, scientific understanding, capital markets credibility, and commercial execution experience as particularly relevant as the company continues to scale its international operations. According to Ms Waldron, Ms Halasz’s ability to translate innovation into shareholder value and build sustainable global businesses will be a key asset as Genetic Signatures executes its growth strategy.
Speaking following her appointment, Ms Halasz said she was attracted to Genetic Signatures by the strength of its molecular diagnostics platform and its growing global relevance. She said she looked forward to working with the team to expand the company’s international footprint, scale commercial operations, and convert its technological innovation into meaningful commercial outcomes.
Genetic Signatures specialises in infectious disease diagnostics, using its patented 3base® technology to simplify pathogen detection and enable laboratories to screen for multiple infections in a single test. The company has established a growing international presence, with direct operations in Australia, the United States, and Europe, supported by global distribution partnerships.
Ms Halasz will formally commence as Chief Executive Officer on 2 March 2026. In parallel, the company confirmed that the search for a permanent Chief Financial Officer is progressing well.